chemical structure of tirzepatide (LY3298176) sodium | GIP/GLP-1 Receptor Agonist | CAS 2023788-19-2 (free base) Tirzepatide a novel anti diabetic
Description
Remember, gentle care is key
J Diabetes Res 2018:1232583 Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V (2020) Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment
However, these medications are FDA-approved for type 2 diabetes treatment, not weight loss
The subcutaneous tissue in each body region has slightly different blood flow patterns and fat density, meaning that using the same spot repeatedly may alter how quickly the medication enters the bloodstream
Sex differences in the weight response to GLP-1RA in people with type 2 diabetes
